Filing Details

Accession Number:
0001209191-18-055372
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-17 17:29:03
Reporting Period:
2018-10-15
Accepted Time:
2018-10-17 17:29:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737287 Allogene Therapeutics Inc. ALLO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1296549 Arie Belldegrun 210 East Grand Avenue
South San Francisco CA 94080
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-15 35,000 $18.00 35,000 No 4 P Direct
Common Stock Acquisiton 2018-10-15 142,248 $0.00 3,710,006 No 4 C Indirect See footnote
Common Stock Acquisiton 2018-10-15 5,989,352 $0.00 5,989,352 No 4 C Indirect See footnote
Common Stock Acquisiton 2018-10-15 1,497,336 $0.00 1,497,336 No 4 C Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2018-10-15 27,095 $0.00 142,248 $0.00
Common Stock Series A Convertible Preferred Stock Disposition 2018-10-15 1,140,829 $0.00 5,989,352 $0.00
Common Stock Series A Convertible Preferred Stock Disposition 2018-10-15 285,207 $0.00 1,497,336 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 488,250 Indirect See footnote
Footnotes
  1. Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.
  2. The securities are held in the name of the Belldegrun Family Trust.
  3. The securities are held by VVAG Special Fund LLC (VVAG), of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  4. The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  5. The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.